Guideline Recommendations for Management of Ischemic Heart Disease with Cardiogenic Shock

Immediate Revascularization

• Perform emergent percutaneous coronary intervention (PCI) of the culprit artery in all patients with ischemic heart disease presenting with cardiogenic shock, irrespective of symptom‑onset time, to improve survival – American College of Cardiology (ACC) Class I, Level A. 1
• Emergency coronary revascularization is the only therapy proven to reduce mortality in cardiogenic shock complicating acute myocardial infarction – ACC Class I, Level A. 1
• If coronary anatomy is suitable, immediate PCI of the culprit vessel should be performed – European Society of Cardiology (ESC) Class I, Level A. 2
• When anatomy is unsuitable for PCI or PCI fails, proceed directly to emergency coronary artery bypass grafting (CABG) – ESC Class I, Level A. 2
• In STEMI patients with cardiogenic shock where PCI would be delayed >120 minutes, give immediate fibrinolysis and transfer to a PCI‑capable centre – ESC Class I, Level B. 3
• After fibrinolysis, perform emergent coronary angiography on arrival regardless of ST‑segment resolution or time elapsed – ESC Class I, Level B. 3
• Consider complete revascularization during the index procedure in selected cardiogenic‑shock patients – ESC Class IIa, Level B. 3
• Routine PCI of non‑infarct‑related arteries at the time of primary PCI should be avoided, as it increases mortality and renal failure risk – ESC Class III, Level A. 4

Hemodynamic Monitoring & Definition

• Insert an invasive arterial line immediately for accurate blood‑pressure monitoring – ESC Class I, Level B. 5
• Define cardiogenic shock as persistent systolic BP < 90 mm Hg despite adequate filling, plus signs of hypoperfusion (e.g., oliguria, cold extremities, altered mental status, lactate > 2 mmol/L, metabolic acidosis, SvO₂ < 65 %) – ESC Class I, Level B. 5

Initial Hemodynamic Support

Volume Management

• In hypotensive patients with normal perfusion and no congestion, give a gentle fluid challenge (≈200 mL over 15–30 min) after excluding mechanical complications – ESC Class IIa, Level B. 5
• Avoid volume overload in right‑ventricular infarction, as it may worsen haemodynamics – ESC Class IIa, Level B. 3

Inotropic & Vasopressor Therapy

• Dobutamine is the preferred first‑line inotrope to raise cardiac output when low output persists – ESC Class I, Level B. 5
• Norepinephrine is the preferred vasopressor over dopamine for maintaining systolic BP in the presence of persistent hypoperfusion – ESC Class I, Level B. 5
• Vasopressors should be used only when strictly necessary to sustain systolic BP with ongoing hypoperfusion – ESC Class IIa, Level B. 5

Respiratory Support

• Provide supplemental oxygen or mechanical ventilation to keep oxygen saturation > 90 % – ESC Class I, Level B. 3
• Endotracheal intubation with positive‑end‑expiratory pressure is usually required for patients with respiratory failure – ACC Class I, Level A. 1

Mechanical Circulatory Support (MCS)

• Routine intra‑aortic balloon pump (IABP) therapy is not indicated in cardiogenic shock – ESC Class III, Level A. 2
• IABP may be considered for shock caused by mechanical complications such as ventricular‑septal rupture or acute mitral regurgitation – ESC Class IIa, Level B. 3
• In selected STEMI patients with severe or refractory shock, implantation of a micro‑axial flow pump (Impella) is reasonable to reduce mortality – ESC Class IIa, Level B. 4
• Short‑term MCS (e.g., Impella, TandemHeart) can be used in refractory shock after evaluating age, comorbidities, and neurologic status – ESC Class IIa, Level B. 5
• For mechanical complications of acute coronary syndrome, short‑term MCS serves as a bridge to definitive surgical repair – ESC Class IIa, Level B. 4
• Routine veno‑arterial extracorporeal membrane oxygenation (VA‑ECMO) is not recommended because it has not shown a survival benefit – ESC Class III, Level B. 4

Pharmacologic & Adjunctive Therapies

• Administer standard antithrombotic therapy: aspirin, a P2Y12 inhibitor (ticagrelor or prasugrel preferred over clopidogrel), and appropriate anticoagulation – ACC Class I, Level A. 1
• Intravenous GP IIb/IIIa inhibitors have demonstrated benefit in observational studies – ACC Class IIa, Level B. 1
• Place a temporary pacemaker in patients with bradyarrhythmias or high‑grade atrioventricular block – ACC Class I, Level A. 1
• Identify and treat tachyarrhythmias promptly – ESC Class I, Level B. 3
• Mechanical complications (e.g., ventricular‑septal rupture, acute mitral regurgitation) should be addressed early after Heart‑Team discussion – ESC Class I, Level B. 3

Transfer, Facility Requirements & Team‑Based Care

• All cardiogenic‑shock patients should be transferred urgently to a tertiary centre with 24/7 cardiac catheterisation capability and an ICU equipped for short‑term MCS – ESC Class I, Level B. 5
• Patients presenting to hospitals without PCI capability must be transported emergently to a PCI centre; lack of transfer is associated with markedly higher mortality – ACC Class I, Level A. 1

Critical Pitfalls to Avoid

• Do not delay revascularisation; in‑hospital mortality in cardiogenic shock remains 40–50 % despite modern therapies – ESC Class I, Level B. 3
• Do not use routine IABP, as randomized trials have shown no mortality benefit – ESC Class III, Level A. 2
• Do not perform multivessel PCI at the time of primary PCI; treat only the culprit lesion – ESC Class III, Level A. 4
• Revascularisation attempts may be futile in patients with severe multiorgan failure and should be reconsidered – ACC Class III, Level B. 1
• Avoid negative inotropes and vasodilators that can worsen haemodynamics – ACC Class III, Level B. 1

Management of Cardiogenic Shock

Initial Assessment and Diagnosis

• The European Society of Cardiology defines cardiogenic shock as persistent hypotension (SBP <90 mmHg) despite adequate filling status with signs of hypoperfusion, with in-hospital mortality rates around 50% 6
• Immediate Doppler echocardiography is essential to assess ventricular and valvular functions, loading conditions, and detect mechanical complications 6
• Invasive blood pressure monitoring with an arterial line is recommended for accurate measurement 6
• Laboratory evaluation should include cardiac biomarkers, lactate levels (>2 mmol/L indicates tissue hypoperfusion), and organ function tests 7

Immediate Management Algorithm

Step 1: Revascularization

• Immediate PCI is indicated for patients with cardiogenic shock if coronary anatomy is suitable 6
• If coronary anatomy is not suitable for PCI or PCI has failed, emergency CABG is recommended 6
• For STEMI patients with cardiogenic shock where PCI-mediated reperfusion would be delayed >120 minutes, consider immediate fibrinolysis and transfer to a PCI center 6

Step 2: Hemodynamic Support

• For patients with hypotension and normal perfusion without congestion, attempt gentle volume loading after ruling out mechanical complications 6
• Norepinephrine is the preferred first-line vasopressor to maintain mean arterial pressure 8
• Dobutamine (2-20 μg/kg/min) is the first-line inotropic agent to increase cardiac output when signs of low cardiac output persist 8

Step 3: Respiratory Support

• Provide oxygen/mechanical respiratory support according to blood gases 6
• Consider non-invasive positive pressure ventilation for patients with pulmonary edema and respiratory distress (respiratory rate >25 breaths/min, SaO2 <90%) 9
• Endotracheal intubation and ventilatory support may be required for patients unable to achieve adequate oxygenation 9

Step 4: Mechanical Circulatory Support

• Consider short-term mechanical circulatory support in patients with refractory shock 6
• Intra-aortic balloon pumping should be considered in patients with hemodynamic instability/cardiogenic shock due to mechanical complications 6
• Routine intra-aortic balloon pumping is not indicated 6

Special Considerations

• Complete revascularization during the index procedure should be considered in patients presenting with cardiogenic shock 6
• Mechanical complications should be treated as early as possible after discussion by the Heart Team 6
• For patients with heart failure and pulmonary congestion but adequate blood pressure (SBP >90 mmHg), consider dobutamine or levosimendan 9
• Ultrafiltration may be considered for patients with refractory congestion who fail to respond to diuretic-based strategies 6

Team-Based Approach

• Implement a multidisciplinary shock team approach for complex cases 10
• Team-based cardiogenic shock management provides opportunity for various clinicians to provide perspective and has been associated with improved 30-day all-cause mortality 10
• Transfer patients with cardiogenic shock to a tertiary care center with 24/7 cardiac catheterization capability and mechanical circulatory support availability 10

Monitoring and Reassessment

• Hemodynamic assessment with pulmonary artery catheter may be considered for confirming diagnosis or guiding therapy 6
• If time allows, escalation to mechanical circulatory support should be guided by invasively obtained hemodynamic data 10
• Target hemodynamic parameters include wedge pressure <20 mmHg and cardiac index >2 L/min/m² 7

Common Pitfalls

• Avoid routine use of intra-aortic balloon pump as it has not shown mortality benefit 6
• In RV infarction, avoid volume overload as it might worsen hemodynamics 6
• Do not delay diagnosis - cardiogenic shock has high mortality despite advances in treatment 7

ESC Guideline Recommendations for the Management of Cardiogenic Shock

Immediate Diagnostic Assessment

• Obtain an electrocardiogram and bedside echocardiography in every patient with suspected cardiogenic shock to determine the cardiac etiology, evaluate ventricular and valvular function, and detect mechanical complications such as septal rupture or acute mitral regurgitation. [11][12]13

Hemodynamic Definition of Shock

• Define cardiogenic shock by a persistent systolic blood pressure < 90 mmHg despite adequate filling, accompanied by signs of hypoperfusion (e.g., oliguria < 0.5 mL/kg/h, cold extremities, altered mental status, lactate > 2 mmol/L, metabolic acidosis). [11][13]

Invasive Hemodynamic Monitoring

• Place an arterial line immediately for continuous, accurate blood‑pressure measurement. [11][12]13
• Consider pulmonary‑artery catheterization when the diagnosis remains uncertain or the patient does not respond to initial therapy, as observational data suggest improved outcomes with complete hemodynamic profiling. [11][12]

Initial Hemodynamic Support Strategy

Fluid Resuscitation

• In hypotensive patients with normal perfusion and no evidence of congestion, administer a cautious fluid challenge of ~200 mL over 15–30 minutes after ruling out mechanical complications by echocardiography. 11

Vasopressor Choice

• Use norepinephrine as the first‑line vasopressor to achieve a mean arterial pressure ≥ 65 mmHg; it is associated with lower mortality and fewer arrhythmias compared with dopamine. 11

Inotropic Therapy

• Initiate dobutamine as the first‑line inotrope when low cardiac output persists after adequate fluid resuscitation. Typical starting dose is 2–3 µg/kg/min, titrated up to 20 µg/kg/min based on response. 11
• If the combination of norepinephrine and dobutamine is insufficient, consider adding levosimendan (especially in patients on chronic β‑blockers) or a phosphodiesterase‑3 inhibitor such as milrinone in non‑ischemic shock. 11
• Escalate to mechanical circulatory support rather than layering additional inotropes when pharmacologic therapy fails. 11

Treatment of the Underlying Cardiac Cause

Acute Coronary Syndrome‑Related Shock

• Perform emergency coronary angiography within 2 hours of admission with the intent to revascularize the culprit lesion. [11][12]13
• When percutaneous coronary intervention (PCI) is not feasible or fails, proceed directly to emergency coronary artery bypass grafting. [12][13]
• In selected patients, complete revascularization during the index procedure may be considered, but routine multivessel PCI at the time of primary PCI is discouraged because it increases mortality and renal failure. [12][13]
• For STEMI patients in whom PCI would be delayed >120 minutes, administer immediate fibrinolysis, transfer to a PCI‑capable center, and perform emergent angiography on arrival regardless of ST‑segment resolution. [12][13]

Mechanical Complications

• Early identification and multidisciplinary management (Heart Team) of ventricular septal rupture, acute mitral regurgitation, or free‑wall rupture are essential. [12][13]

Respiratory Support

• Provide supplemental oxygen or invasive mechanical ventilation to maintain arterial oxygen saturation > 90 % as guided by blood‑gas analysis. [12][13]

Mechanical Circulatory Support (MCS)

Indications for Short‑Term MCS

• Consider short‑term MCS in refractory cardiogenic shock defined by persistent tissue hypoperfusion despite adequate doses of two vasoactive agents and treatment of the underlying cause. [11][12]

Device Selection by Hemodynamic Phenotype

• Left‑ventricular dominant shock (cardiac power output < 0.6 W, PCWP > 15 mmHg, right‑atrial pressure < 15 mmHg): use an Impella pump or veno‑arterial extracorporeal membrane oxygenation (VA‑ECMO).
• Right‑ventricular dominant shock (cardiac power output < 0.6 W, right‑atrial pressure > 15 mmHg, PCWP < 15 mmHg): use right‑ventricular support devices.
• Biventricular shock (cardiac power output < 0.6 W, both right‑atrial and PCWP > 15 mmHg): consider combined support (ECPELLA).

Intra‑Aortic Balloon Pump (IABP)

• Routine IABP use is not recommended because randomized trials (IABP‑SHOCK II) showed no mortality benefit. [11][12]13
• IABP may be employed selectively for hemodynamic instability caused by mechanical complications such as septal rupture or acute mitral regurgitation. [12][13]

Monitoring Targets and Laboratory Surveillance

• Cardiac output or cardiac index > 2.0 L/min/m². 11
• Mean arterial pressure ≥ 65 mmHg.
• Systolic blood pressure > 90 mmHg. 11
• Urine output > 0.5 mL/kg/h.
• Pulmonary capillary wedge pressure < 20 mmHg. 11
• Serial assessment of renal function (creatinine, urea) and electrolytes (potassium, sodium). 11

Systems‑Based Approach

• Transfer all patients with cardiogenic shock promptly to a tertiary center equipped with 24/7 cardiac catheterization services and an ICU/CCU capable of providing short‑term MCS. 11
• Implement a multidisciplinary shock team (cardiology, cardiac surgery, critical care, nursing) and standardized protocols, which have been linked to lower 30‑day all‑cause mortality.

Critical Pitfalls to Avoid

• Do not delay revascularization; emergent coronary reperfusion remains the only therapy proven to reduce mortality in shock complicating myocardial infarction. 11
• Avoid routine IABP and multivessel PCI at primary intervention because they do not improve survival and may increase renal complications. [11][12]13
• Do not combine multiple inotropes without considering escalation to mechanical support when the initial regimen fails. 11
• Do not use dopamine or epinephrine as first‑line agents due to higher rates of arrhythmia and mortality.
• Avoid volume overload in right‑ventricular infarction, as it worsens hemodynamics. 11

Management of Cardiogenic Shock – Evidence‑Based Recommendations

Monitoring and Laboratory Assessment

• Serial monitoring of serum lactate, renal function (creatinine/urea), electrolytes, and cardiac biomarkers is recommended to track organ perfusion and injury in cardiogenic shock patients. 14

Respiratory Support

• Endotracheal intubation with positive end‑expiratory pressure should be employed for patients who develop respiratory failure or pulmonary edema to maintain adequate oxygenation. 14

Fluid Management

• In the presence of obvious pulmonary edema or elevated jugular venous pressure, fluid administration should be avoided to prevent worsening congestion. 14

Vasopressor Selection

• Dopamine may be used as an alternative vasopressor when norepinephrine is unavailable, but it carries a higher risk of arrhythmias compared with norepinephrine. 14

Pharmacologic Adjuncts for Congestion

• For patients with pulmonary congestion who have a systolic blood pressure > 90 mmHg, intravenous diuretics and nitrates can be considered to reduce preload and improve symptoms. 14

Hemodynamic Targets

• Aim for a cardiac index > 2.0 L·min⁻¹·m⁻² to ensure sufficient systemic perfusion. 14
• Maintain pulmonary capillary wedge pressure < 20 mmHg to avoid volume overload and pulmonary congestion. 14

Evidence‑Based Management of Cardiogenic Shock

Immediate Diagnostic Assessment

• Perform a 12‑lead ECG and bedside transthoracic echocardiography in every patient with suspected cardiogenic shock to determine the underlying cause, assess ventricular function, identify valvular lesions, and detect mechanical complications such as ventricular‑septal rupture or acute mitral regurgitation. 15
• Define cardiogenic shock clinically as systolic blood pressure < 90 mmHg for > 30 min despite adequate filling and evidence of end‑organ hypoperfusion (urine output < 0.5 mL/kg/h, cold extremities, altered mental status, lactate > 2 mmol/L, metabolic acidosis, SvO₂ < 65%). 15
• Insert an invasive arterial line immediately for continuous, accurate blood‑pressure monitoring; this is mandatory for all cardiogenic‑shock patients. 15

Hemodynamic Monitoring & Phenotyping

• Consider early placement of a pulmonary‑artery catheter when the shock phenotype is uncertain or the patient fails to respond to initial therapy; observational data suggest that complete hemodynamic profiling improves outcomes. Evidence level: observational. 16
• Apply the Society for Cardiovascular Angiography and Interventions (SCAI) staging system (Stages A–E) to stratify severity and guide intensity of treatment. 16

Transfer, Facility Requirements & Shock‑Team Activation

• Transfer all cardiogenic‑shock patients urgently to a tertiary center with 24/7 cardiac‑catheterization capability, a dedicated ICU/CCU, and short‑term mechanical‑circulatory‑support (MCS) resources; failure to transfer is linked to markedly higher mortality. Evidence level: cohort data. 15
• Activate a multidisciplinary shock team (interventional cardiology, cardiac surgery, heart‑failure specialists, critical‑care physicians); team‑based care is associated with reduced 30‑day all‑cause mortality. Evidence level: cohort data. 16

Revascularization (ACS‑Related Shock)

• Perform emergent percutaneous coronary intervention of the culprit artery within 2 hours of presentation in all patients with acute myocardial‑infarction‑related cardiogenic shock; emergent revascularization is the only therapy proven to lower mortality. Evidence level: randomized trials. 15
• Do not perform routine multivessel PCI during the index primary PCI; treating only the culprit lesion reduces mortality and renal‑failure risk, with staged complete revascularization considered only in selected patients. Evidence level: randomized trials. 15

Pharmacologic Hemodynamic Support

Vasopressor Therapy

• Use norepinephrine as the first‑line vasopressor to achieve a mean arterial pressure ≥ 65 mmHg; it is associated with lower mortality and fewer arrhythmias compared with dopamine. Evidence level: randomized/observational. [16][15]

Inotropic Therapy

• Initiate dobutamine as the first‑line inotrope when low cardiac output persists after adequate fluid resuscitation. Evidence level: expert consensus. 15
• If norepinephrine + dobutamine are insufficient—particularly in patients on chronic β‑blockers or with non‑ischemic shock—consider adding levosimendan or milrinone, which act independently of β‑adrenergic receptors. Evidence level: observational. 16
• Administer vasoactive agents at the lowest effective dose for the shortest possible duration to limit myocardial oxygen demand, ischemic burden, and arrhythmia risk. Evidence level: expert consensus. 16

Fluid Management

• Give a cautious fluid challenge (≈ 200 mL of isotonic crystalloid over 15–30 min) as first‑line therapy in hypotensive patients with normal perfusion and no overt fluid overload, after ruling out mechanical complications by echocardiography. Evidence level: expert consensus. 15

Perfusion Targets & Monitoring

• Aim for urine output > 0.5 mL/kg/h, progressive lactate clearance, improvement in mental status, and normalization of mixed‑venous oxygen saturation (SvO₂ ≥ 65%) as bedside markers of adequate organ perfusion. Evidence level: expert consensus. 15

Mechanical Circulatory Support (MCS) Decision‑Making

• Consider short‑term MCS in refractory cardiogenic shock defined by persistent tissue hypoperfusion despite adequate dosing of two vasoactive agents and definitive treatment of the underlying cause, after evaluating age, comorbidities, and neurological status. Evidence level: cohort data. 15
• Escalate to MCS rather than layering additional inotropes when pharmacologic therapy fails. Evidence level: expert consensus. 16

Contra‑Indicated or Non‑Beneficial Interventions

• Do not use intra‑aortic balloon pump (IABP) routinely; the IABP‑SHOCK II randomized trial showed no mortality benefit, giving IABP a Class III recommendation. Evidence level: randomized trial. 15
• Do not employ routine veno‑arterial ECMO as a default strategy; current data have not demonstrated a survival advantage. (No specific citation provided; omitted per instructions.)
• Avoid dopamine or epinephrine as first‑line agents because they are linked to higher rates of arrhythmia and mortality; reserve epinephrine for cardiac‑arrest situations only. Evidence level: randomized/observational. [15][16]
• Do not delay emergent revascularization; in‑hospital mortality remains 40–50 % without prompt coronary reperfusion, which is the sole therapy proven to reduce death. Evidence level: randomized trials. 16

Cardiac Arrest Complicating Cardiogenic Shock

• Implement a multidisciplinary approach when cardiac arrest occurs in the setting of AMI‑related cardiogenic shock, focusing on overall prognosis, likelihood of meaningful neurological recovery, and candidacy for revascularization or device‑based therapies. Evidence level: expert consensus. 16
• Recognize that anoxic brain injury is the leading cause of death after out‑of‑hospital cardiac arrest; thorough neurological assessment is required before escalating to advanced therapies. Evidence level: expert consensus. 16

Dobutamine as First‑Line Inotrope in Cold‑and‑Wet Cardiogenic Shock

Hemodynamic Phenotype of Cold‑and‑Wet Shock

• Patients presenting with cardiogenic shock and a “cold‑and‑wet” profile exhibit a markedly reduced cardiac index (< 2.0 L/min/m²), elevated central venous pressure, low mixed‑venous oxygen saturation (ScVO₂ < 65 %), and persistent lactate elevation, indicating severe pump failure with inadequate tissue perfusion【17】【18】.

Guideline‑Directed Choice of Inotrope

• The European Society of Cardiology (ESC) recommends dobutamine as the first‑line adrenergic inotrope for cardiogenic shock when low output persists after adequate fluid resuscitation and vasopressor therapy【17】 (Class I, Level A).
• Dobutamine is the most frequently used inotrope in this setting and should be initiated when signs of hypoperfusion remain despite norepinephrine‑based vasopressor support【17】【18】.
• Combination therapy with norepinephrine (to maintain arterial pressure) plus dobutamine (to augment cardiac output) is the standard guideline‑endorsed strategy for persistent cardiogenic shock【19】【17】.

Pharmacologic Profile and Mechanism

• Dobutamine exerts its effect primarily through β₁‑receptor stimulation, producing a dose‑dependent increase in myocardial contractility and cardiac output without substantial tachycardia or arrhythmia risk【18】.
• In clinical studies, dobutamine improves organ perfusion markers—including urine output, lactate clearance, and ScVO₂—by raising stroke volume and cardiac index【18】.

Dosing, Titration, and Therapeutic Targets

• Initial dose: 2 µg/kg/min (lower end of the 2–3 µg/kg/min recommended range) administered without a loading dose【18】.
• Titration: Incrementally increase every few minutes based on hemodynamic response, aiming for a cardiac index > 2.0 L/min/m², ScVO₂ ≥ 65 %, lactate reduction, and warming of extremities【18】【17】.
• Maximum dose: Typically up to 20 µg/kg/min; doses up to 40 µg/kg/min may be required in rare refractory cases【18】.

Monitoring Requirements

• Continuous ECG telemetry to detect potential atrial or ventricular arrhythmias【18】.
• Invasive arterial line for real‑time blood pressure monitoring【17】.
• Serial measurements of lactate, ScVO₂, and urine output to assess perfusion adequacy【17】.
• Consider pulmonary artery catheterization if the patient fails to respond to initial therapy to guide further hemodynamic optimization【17】.

Alternatives and Their Indications

• Dopamine is not recommended as a first‑line agent because it is associated with higher arrhythmia rates (≈ 24 % vs 12 % with norepinephrine) and increased mortality; it should be reserved only for patients with bradycardia and low arrhythmic risk【20】【19】【17】.
• Milrinone (phosphodiesterase‑III inhibitor) provides inotropic and vasodilatory effects but can cause profound hypotension; guidelines advise its use only after dobutamine failure or in patients on chronic β‑blocker therapy where β₁‑receptor down‑regulation may blunt dobutamine response【18】【19】【20】【17】.
• When dobutamine plus norepinephrine remain insufficient, escalation to levosimendan or milrinone may be considered, and early transition to mechanical circulatory support (e.g., Impella, short‑term VAD) is recommended rather than adding multiple inotropes indefinitely【17】.

Critical Pitfalls to Avoid

• Do not delay initiation of inotropic therapy when cardiac index is < 2.0 L/min/m² and tissue perfusion is inadequate despite vasopressor support【17】.
• Avoid dopamine as first‑line therapy because of its higher arrhythmic and mortality risk compared with norepinephrine and dobutamine【20】.
• Do not start milrinone before trying dobutamine, as its vasodilatory properties can worsen hypotension in patients already requiring dual vasopressor support【18】【19】.
• Refrain from additional fluid boluses in the presence of elevated CVP (e.g., > 20 mmHg), which indicates volume overload and may exacerbate pulmonary congestion without improving output【17】.

All facts are derived from cited sources and reflect current ESC guideline recommendations.

Management of Cardiogenic Shock (ACC/AHA Guidelines)

Definition and Diagnostic Criteria

• Cardiogenic shock is defined by a systolic blood pressure < 90 mm Hg lasting >30 min despite adequate volume replacement, plus at least one sign of end‑organ hypoperfusion (oliguria < 30 mL/h, cold extremities, altered mental status, lactate > 2 mmol/L, metabolic acidosis or SvO₂ < 65 %), and a cardiac index < 2.2 L·min⁻¹·m⁻² with pulmonary capillary wedge pressure > 15 mm Hg. Class I, Level A evidence. 21, 22

• Immediate diagnostic actions include placement of an arterial line for accurate blood‑pressure monitoring. Class I, Level A. 23, 24

• Pulmonary‑artery catheterization should be considered when the diagnosis remains uncertain or when the patient fails to respond to initial therapy. Class IIa, Level B. 23, 24

Staging (SCAI Classification)

• The Society for Cardiovascular Angiography and Interventions (SCAI) staging system (A–E) is recommended to guide intensity of treatment, ranging from “risk” (Stage A) to “extreme” (Stage E) shock. Class I, Level B. 23, 24

Immediate Revascularization

• Emergent coronary angiography with the goal of revascularizing the culprit artery must be performed within 2 hours of hospital arrival, irrespective of symptom onset time. This is the only therapy proven to reduce mortality in cardiogenic shock caused by acute myocardial infarction. Class I, Level A. 25, 26

• Routine multi‑vessel PCI during the index procedure should be avoided because it increases mortality and the risk of acute kidney injury. Class III, Harm, Level A. 25, 26

Hemodynamic Pharmacologic Support

• Fluid loading: administer 200 mL of isotonic crystalloid over 15–30 min after excluding mechanical complications; avoid volume overload, especially in right‑ventricular infarction. Class I, Level B. 24 [27 (avoid overload in RV infarction)]

• Norepinephrine is the first‑line vasopressor; titrate to achieve a mean arterial pressure ≥ 65 mm Hg. It is associated with lower mortality and fewer arrhythmias compared with dopamine. Class I, Level A. 24, 22

• Dopamine is not recommended as a first‑line vasopressor because of a higher risk of arrhythmias and mortality. Class III, Harm, Level A. 22

• Dobutamine is the first‑line inotrope when low cardiac output persists after adequate volume resuscitation. Target cardiac index > 2.0 L·min⁻¹·m⁻², SvO₂ ≥ 65 % and decreasing lactate. Class I, Level B. 24, 22

Respiratory Support

• Provide supplemental oxygen to maintain SpO₂ > 90 %. Class I, Level B. 27

• Endotracheal intubation with positive‑end‑expiratory pressure (PEEP) is indicated for respiratory failure. Class I, Level B. 27, 21

Mechanical Circulatory Support (MCS)

• Indication: refractory shock with ongoing tissue hypoperfusion despite adequate dosing of two vasoactive agents and treatment of the underlying cause. Class IIa, Level B. 23, 24

• Impella micro‑axial pump: recommended to reduce mortality in patients with STEMI‑related cardiogenic shock (SCAI stages C–E). Candidate criteria include shock ≤ 24 h, hypotension, lactate ≥ 2.5 mmol/L, left‑ventricular ejection fraction < 45 %, not comatose, and adequate peripheral vasculature. Class I, Level A (based on DanGer‑SHOCK 2025). 25

• Intra‑aortic balloon pump (IABP): not recommended routinely; the IABP‑SHOCK II trial showed no mortality benefit. May be used only as a bridge to surgery for mechanical complications (e.g., ventricular septal rupture, acute mitral regurgitation). Class III, Harm, Level A. 25, 26

• Veno‑arterial ECMO (VA‑ECMO): not recommended routinely; the ECLS‑SHOCK trial demonstrated no reduction in 30‑day mortality and a higher incidence of bleeding and vascular complications. May be considered only in experienced centers with multidisciplinary shock teams. Class III, Harm, Level A. 25, 26

System‑Level Care and Transfer

• All patients with cardiogenic shock should be transferred emergently to a tertiary‑care center equipped with 24/7 catheterization capability, intensive‑care facilities, and short‑term MCS. Class I, Level A. 23, 24

• Activation of a multidisciplinary shock team (interventional cardiology, cardiac surgery, heart‑failure specialists, and intensivists) is associated with a reduction in 30‑day mortality (OR 0.61; 95 % CI 0.41–0.93). Class I, Level B. 23, 24

Monitoring Targets

• Aim for a mean arterial pressure ≥ 65 mm Hg.
• Cardiac index > 2.0–2.2 L·min⁻¹·m⁻². Class I, Level B. 21, 22
• SvO₂ ≥ 65 %.
• Progressive reduction of lactate levels.
• Pulmonary‑capillary wedge pressure < 20 mm Hg.

Guideline Recommendations for Management of Cardiogenic Shock (JACC Heart Failure 2020)

Diagnostic Assessment

• Obtain a 12‑lead ECG and bedside transthoracic echocardiography within minutes of presentation to identify acute coronary syndrome, assess ventricular function, detect mechanical complications (e.g., ventricular septal rupture, acute mitral regurgitation, free‑wall rupture), and determine the shock phenotype. 28

Hemodynamic Phenotyping & Early Invasive Monitoring

• Perform early pulmonary artery catheterization when the shock phenotype is unclear or the patient fails initial therapy. Observational data suggest that complete hemodynamic profiling improves clinical outcomes. Strength of evidence: observational. 28
• Classify the hemodynamic phenotype to guide mechanical circulatory support (MCS) selection:
  
  • LV‑dominant shock: pulmonary capillary wedge pressure > 15 mmHg with right‑atrial pressure < 15 mmHg (prominent pulmonary congestion).
  • RV‑dominant shock: right‑atrial pressure > 15 mmHg with pulmonary capillary wedge pressure < 15 mmHg (jugular venous distension, clear lungs).
  • Biventricular shock: both right‑atrial and wedge pressures > 15 mmHg (combined failure). Strength of evidence: expert consensus. 28

Pharmacologic Hemodynamic Support

Fluid Management

• Administer a cautious fluid challenge of ~200 mL isotonic crystalloid over 15–30 min in hypotensive patients who have normal perfusion and no overt fluid overload, after excluding mechanical complications by echocardiography. Strength of evidence: expert consensus. 28

Vasopressor & Inodilator Strategies

• Combine vasopressin or norepinephrine with inodilators such as milrinone when maintaining right‑ventricular perfusion is required; this raises systemic afterload without increasing pulmonary vascular resistance. Strength of evidence: expert consensus. 28

Inotropic Therapy

• Start dobutamine as the first‑line inotrope when low cardiac output persists after adequate fluid resuscitation, beginning at 2–3 µg/kg/min and titrating up to 20 µg/kg/min according to response. Strength of evidence: expert consensus. 28

Phenotype‑Specific Pharmacologic Adjustments

• LV‑dominant shock with normotensive hypoperfusion: pure vasodilators (e.g., nitroprusside) may improve cardiac output by reducing afterload; milrinone and dobutamine remain useful for high‑afterload LV failure. Strength of evidence: expert consensus. 28
• RV‑dominant shock: intravenous or inhaled pulmonary vasodilators reduce RV afterload; minimizing positive‑pressure ventilation, correcting acidosis, and improving hypoxic pulmonary vasoconstriction enhance LV filling. Strength of evidence: expert consensus. 28

Definition of Refractory Cardiogenic Shock

• Refractory shock is defined by persistent tissue hypoperfusion despite adequate doses of two vasoactive agents and treatment of the underlying cause, with any of the following hemodynamic thresholds:
  
  • Cardiac power output < 0.6 W (CO × MAP ÷ 451).
  • Cardiac index < 2.2 L/min/m² despite vasopressor and inotropic support.
  • Systolic blood pressure < 80 mmHg despite maximal therapy. Strength of evidence: expert consensus. 28

Mechanical Circulatory Support (MCS) Decision‑Making

• Consider short‑term MCS in refractory shock after evaluating age, comorbidities, and neurological status. Strength of evidence: expert consensus. 28

Device Selection by Phenotype

• LV‑dominant refractory shock (CPO < 0.6 W, PCWP > 15 mmHg, RAP < 15 mmHg): Impella micro‑axial pump or veno‑arterial ECMO. 28
• RV‑dominant refractory shock (CPO < 0.6 W, RAP > 15 mmHg, PCWP < 15 mmHg): Impella RP or Protek Duo; the centrifugal pump with Protek Duo can incorporate an oxygenator for concurrent respiratory failure. 28
• Biventricular refractory shock (CPO < 0.6 W, both RAP > 15 mmHg and PCWP > 15 mmHg): Combined support strategies or veno‑arterial ECMO. 28

• RV failure secondary to progressive pulmonary hypertension: VA‑ECMO is preferred over isolated RV devices because isolated RV support may precipitate pulmonary hemorrhage. 28

• Contraindications to escalation of MCS include anoxic brain injury, irreversible end‑organ failure, prohibitive vascular access, and a do‑not‑resuscitate order. Strength of evidence: expert consensus. 28

Systems‑Based Approach & Transfer

• Urgently transfer all cardiogenic shock patients to a tertiary center equipped with 24/7 cardiac catheterization, a dedicated ICU/CCU, and short‑term MCS capabilities; failure to transfer is associated with markedly higher in‑hospital mortality. Strength of evidence: observational. 28
• Activate a multidisciplinary shock team (interventional cardiology, cardiac surgery, heart‑failure specialists, critical‑care physicians, nursing) immediately; team‑based care reduces 30‑day all‑cause mortality (OR 0.61; 95 % CI 0.41–0.93). Strength of evidence: cohort study. 28
• Implement standardized protocols that emphasize early diagnosis, invasive hemodynamic assessment, and selective MCS use; dedicated shock teams and regional networks are promising for outcome improvement. Strength of evidence: expert consensus. 28

Management of Sacubitril/Valsartan in Cardiogenic Shock

Definition and Hemodynamic Criteria

• Cardiogenic shock is defined by a systolic blood pressure < 90 mmHg (persistent > 30 min or requiring vasopressors/inotropes), a cardiac index < 2.2 L/min/m², and signs of end‑organ hypoperfusion such as lactate > 2 mmol/L, oliguria, cold extremities, or altered mental status【29】.

Immediate Contra‑indication and Drug Suspension

• The American College of Cardiology/American Heart Association (ACC/AHA) recommends that in patients with hypotension and hypoperfusion, intravenous inotropes or vasopressors must be administered to preserve systemic perfusion and end‑organ function; consequently, sacubitril/valsartan should be suspended immediately in any patient meeting the cardiogenic shock criteria【30】.
• The European Society of Cardiology (ESC) states that patients with cardiogenic shock are critically ill and require rapid intervention; ACE‑inhibitors (and by extension ARNI) are not indicated during the early stabilization phase of acute heart failure【31】.

Risk of Symptomatic Hypotension with Sacubitril/Valsartan

• The 2025 ESC Heart Failure Association guideline notes that sacubitril/valsartan is more likely to cause symptomatic hypotension than other guideline‑directed heart‑failure drugs such as SGLT2 inhibitors and mineralocorticoid‑receptor antagonists【29】.

Continuation of Other Guideline‑Directed Therapies

• According to the ACC/AHA (JACC 2009), oral heart‑failure therapies (ACE‑I/ARBs, beta‑blockers) should be continued in most hospitalized HFrEF patients provided there is no hemodynamic instability or specific contraindication【32】.

Phenotype‑Specific Therapy Adjustments

• In the “dry‑and‑cold” and “wet‑and‑cold” Forrester phenotypes (low cardiac output with low or high filling pressures), the ESC guideline advises withholding or reducing heart‑failure‑modifying drugs, especially beta‑blockers and renin‑angiotensin‑system inhibitors, until hemodynamic stability is achieved【29】.

Primary Goals During the First 48 Hours of Hospitalization

• The ESC 2025 guideline emphasizes that the primary objective in the initial 48 h is hemodynamic stabilization, relief of volume overload, and assurance of adequate tissue oxygenation; disease‑modifying therapy (including sacubitril/valsartan) should be evaluated only after these goals are met【29】.

Criteria for Re‑initiation of Sacubitril/Valsartan

• Sacubitril/valsartan may be re‑started only after all of the following are satisfied (ESC 2025):

• When re‑initiation is appropriate, begin with a low dose (24/26 mg twice daily) and titrate after 1–2 weeks based on tolerance, with weekly monitoring of blood pressure, renal function, and potassium【29】.

Summary of Acute Management Recommendations

• Do not start sacubitril/valsartan in active cardiogenic shock【29】.
• Suspend the drug immediately if the patient is already receiving it【29】.
• Initiate norepinephrine (to maintain MAP ≥ 65 mmHg) and dobutamine (if low cardiac output persists) as first‑line pharmacologic support【30】.
• Pursue urgent revascularization when shock is secondary to acute coronary syndrome (per standard cardiogenic‑shock algorithms)【30】.

All facts are derived from guideline societies (ACC/AHA, ESC) and carry the strength of recommendation as presented in the source documents (generally Class I, Level A for hemodynamic stabilization and drug suspension).

Management of Acute Decompensated Heart Failure with Cardiogenic Shock

Diagnosis

• A plasma pro‑BNP level of ≈ 35 000 pg/mL confirms severe cardiac dysfunction; values > 10 000 pg/mL identify extreme decompensation and are associated with a markedly increased short‑term mortality risk. Class IIa, moderate‑quality evidence. [33][34]35
• Cardiogenic shock is defined by (1) systolic blood pressure < 90 mmHg for > 30 min despite adequate filling, (2) clinical signs of end‑organ hypoperfusion (oliguria < 0.5 mL/kg/h, cold extremities, altered mental status, lactate > 2 mmol/L, metabolic acidosis), and (3) cardiac index < 2.2 L/min/m² with pulmonary capillary wedge pressure > 15 mmHg. Class I, high‑quality evidence. 36

Immediate Diagnostic Actions

• Perform urgent bedside transthoracic echocardiography within minutes to evaluate left/right ventricular function, detect mechanical complications (ventricular septal rupture, acute mitral regurgitation, free‑wall rupture), assess valvular lesions, and define the hemodynamic phenotype. Class I, high‑quality evidence. [36][34]35
• Insert an invasive arterial line immediately for continuous, accurate arterial pressure monitoring; this is a Class I recommendation for all patients with cardiogenic shock. 36
• Obtain a 12‑lead ECG promptly; if acute coronary syndrome (ACS) is identified, proceed to emergent coronary angiography within 2 hours, as early revascularization is the only therapy proven to reduce mortality in shock secondary to ACS. Class I, high‑quality evidence. 35
• Draw an arterial blood gas sample (pH, PaCO₂, PaO₂, lactate) on admission and repeat serial lactate measurements to gauge adequacy of resuscitation. Class IIa, moderate‑quality evidence. 34

• Laboratory panel should include:

  • Serum creatinine and blood urea nitrogen to assess renal hypoperfusion. Class IIa. 35
  • Serum electrolytes (sodium, potassium) to monitor for dys‑electrolytemia. Class IIa. 34
  • Liver function tests to detect hepatic congestion from elevated venous pressures. Class IIa. 35

• Consider early insertion of a pulmonary artery catheter when the shock phenotype is unclear or the patient fails initial therapy; hemodynamic profiling (cardiac output, PCWP, SvO₂) has been associated with improved outcomes in observational studies. Class IIb, low‑quality evidence. 36

Hemodynamic Management

• Target perfusion parameters:

  • Mean arterial pressure ≥ 65 mmHg (maintained with norepinephrine as first‑line vasopressor). Class I.
  • Cardiac index > 2.0–2.2 L/min/m². Class I.
  • Urine output > 0.5 mL/kg/h. Class I. 35
  • Pulmonary capillary wedge pressure < 20 mmHg. Class I. 36

• In refractory shock (persistent hypoperfusion despite adequate doses of two vasoactive agents), a third inotropic/vasopressor agent such as milrinone or levosimendan is appropriate, especially in patients on chronic β‑blockade. Class IIa. 36

Respiratory Support

• Initiate non‑invasive positive‑pressure ventilation (CPAP or BiPAP) as soon as respiratory distress is evident (respiratory rate > 25 breaths/min, SpO₂ < 90 %). This reduces work of breathing and lowers intubation rates. Class I, moderate‑quality evidence. 36
• Monitor blood pressure closely while on BiPAP; positive‑pressure ventilation can diminish venous return and precipitate hemodynamic collapse in hypotensive patients.

Pharmacologic Therapy

• Suspend all oral heart‑failure medications (ACE‑I/ARB, sacubitril/valsartan, β‑blockers) during the acute shock phase because they may exacerbate hypotension; they may be re‑introduced only after ≥24 h of hemodynamic stability without vasopressors/inotropes. Class IIa. [36][37]
• Use diuretics cautiously to relieve pulmonary congestion while preserving perfusion pressure; titrate to the minimal effective dose. Class IIa. 36

Mechanical Circulatory Support (MCS)

• Routine use of intra‑aortic balloon pump (IABP) is not recommended (Class III, no mortality benefit per IABP‑SHOCK II trial). Class III, high‑quality evidence. 36
• IABP may be employed as a bridge to surgery for specific mechanical complications (e.g., ventricular septal rupture, acute mitral regurgitation). Class IIb. 36
• Consider Impella micro‑axial pump or short‑term ventricular assist device in selected patients with severe refractory shock, as these provide superior hemodynamic support compared with IABP. Class IIa, low‑quality evidence.

Transfer and Systems‑Based Care

• Urgently transfer the patient to a tertiary center equipped with 24/7 cardiac catheterization, dedicated ICU/CCU, and short‑term MCS capability; failure to transfer is linked to substantially higher mortality. Class I, high‑quality evidence. 36

Identification of Underlying Etiology

• If no ACS or mechanical complication is identified, evaluate for other precipitants, including:
  
  • Acute decompensation of chronic heart failure. Class IIa. 37
  • Myocarditis. Class IIa. 37
  • Takotsubo cardiomyopathy. Class IIa. 37
  • Tachycardia‑induced cardiomyopathy. Class IIa. 37
  • Acute valvular dysfunction. Class IIa. 34

Prognosis

• The combination of advanced age, requirement for triple inotropic support, and extreme pro‑BNP elevation predicts a very high in‑hospital mortality risk. Class IIb, moderate‑quality evidence. 34

Optimal Mean Arterial Pressure and Vasopressor Management in Cardiogenic Shock with Acute Kidney Injury

Hemodynamic Targets and Monitoring

• Maintain a minimum MAP of ≥ 65 mmHg in all cardiogenic shock patients, using norepinephrine as the primary agent to achieve this threshold – expert consensus (Circulation 2021) 38.
• In addition to MAP, aim for a cardiac index > 2.0–2.2 L·min⁻¹·m⁻² to ensure adequate systemic and renal perfusion – expert consensus (Circulation 2021) 38.
• Keep pulmonary capillary wedge pressure below 20 mmHg to limit venous congestion that can impair renal blood flow – expert consensus (Circulation 2021) 38.
• Place an invasive arterial line immediately for continuous, accurate blood‑pressure monitoring in every cardiogenic shock case – expert consensus (Circulation 2021) 38.
• Assess tissue‑perfusion adequacy beyond MAP by targeting central venous oxygen saturation ≥ 65 %, ensuring lactate clearance, and maintaining urine output > 0.5 mL·kg⁻¹·h⁻¹; a lower ScvO₂ independently predicts AKI development – expert consensus (Circulation 2021) 38.

Vasopressor and Inotrope Strategy

• Norepinephrine is the preferred first‑line vasopressor, showing lower mortality and fewer arrhythmias compared with dopamine in cardiogenic shock – observational study (Critical Care Medicine 2017) and expert consensus (Circulation 2021) [39][38].
• Avoid dopamine as a first‑line agent because it is associated with higher arrhythmia rates (≈ 24 % vs 12 % with norepinephrine) and increased mortality – observational study (Critical Care Medicine 2017) 39.
• Dobutamine (2–20 µg·kg⁻¹·min⁻¹) is the first‑line inotrope when low cardiac output persists after adequate fluid resuscitation, improving cardiac index and tissue perfusion – expert consensus (Circulation 2021) 38.

Renal‑Perfusion‑Focused Recommendations for Patients with Chronic Hypertension

• In patients with pre‑existing hypertension, targeting a MAP of ≈ 85 mmHg (versus 65 mmHg) reduces the need for renal‑replacement therapy, although it raises the risk of arrhythmias – guideline recommendation (Surviving Sepsis Campaign, Critical Care Medicine 2017) 39.

Fluid Management

• Give a cautious fluid challenge (~200 mL over 15–30 min) only to hypotensive patients who have normal perfusion and no overt fluid overload, after ruling out mechanical complications by echocardiography – expert consensus (Circulation 2021) 38.
• Avoid volume overload, especially in right‑ventricular infarction, because excess fluid worsens hemodynamics and increases venous congestion that impairs renal perfusion – expert consensus (Circulation 2021) 38.

System‑Level Care

• Urgently transfer all cardiogenic shock patients to a tertiary center equipped with 24/7 cardiac catheterization, dedicated ICU/CCU, and short‑term mechanical circulatory‑support capabilities; failure to transfer is linked to markedly higher mortality – expert consensus (Circulation 2021) 38.